A cooperative research project has been agreed upon between Graft Polymer’s partner and Nottingham University

2 min read | October 15, 2024 03:18 AM EDT | By Team Kalkine Media

Google News:

A cooperative research project has been agreed upon between Graft Polymer’s partner and Nottingham University — Image source: Shutterstock

Recent News

Why Did WSP Global (TSX:WSP) Gain on UK Execution Shift in TSX 60?

Why Did Aecon Group (TSX:ARE) Gain on Churchill MOU in TSX Index?

Why Did Endeavour Silver (TSX:EDR) Gain on Terronera Drill Results in...

Why Did Maple Leaf Foods (TSX:MFI) Stock Dip After TSX Index Restructu...

Make Kalkine Media
My Trusted Source

Highlights:

Graft Polymer (UK) PLC announces a research agreement between its partner, Awakn Life Sciences, and the University of Nottingham to study a new chemical compound aimed at improving social cognition and pro-social behaviors.
The research, led by Dr. Madeleine King, will utilize rodent models to assess the therapeutic potential of the co-developed compound in treating mental health conditions like post-traumatic stress disorder (PTSD).
This initiative is part of Graft Polymer's ongoing commitment to develop innovative therapies for mental health, addressing critical needs in trauma-related disorders.

Graft Polymer (UK) PLC (LSE:GPL) has announced that its partner, Awakn Life Sciences, has entered into a research agreement with the University of Nottingham. This collaborative study will investigate a new chemical compound co-developed by both companies, focusing on its potential to enhance social cognition and pro-social behaviors, which are crucial in the treatment of mental health conditions such as post-traumatic stress disorder (PTSD).

The research will be led by Dr. Madeleine King, a recognized expert in behavioral neuroscience. The study aims to evaluate the compound's efficacy using rodent models through a method known as the social transmission of food preferences. This approach will help assess how the compound influences social behaviors, providing valuable insights into its therapeutic potential.

Anticipated to conclude by the end of 2024, this study represents a significant milestone in the pursuit of new treatments for trauma-related disorders. The initiative aligns with Graft Polymer's mission to develop innovative therapies that address pressing mental health issues affecting millions of individuals worldwide.

Graft's CEO, Anthony Tennyson, highlighted the importance of this collaboration, stating, "This is a significant step forward in our joint programme with Awakn. The in vivo testing at the University of Nottingham will be pivotal in assessing the therapeutic potential of our novel aminoindane compounds, bringing us closer to addressing the unmet needs in trauma-related mental health disorders."

By advancing research in this area, Graft Polymer and Awakn Life Sciences aim to contribute to the development of effective treatments that can significantly improve the quality of life for individuals suffering from trauma-related mental health conditions. This partnership underscores the commitment of both organizations to push the boundaries of mental health therapy through scientific innovation and collaboration.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.